Detalles de la búsqueda
1.
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.
Blood
; 143(14): 1355-1364, 2024 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38127586
2.
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Blood
; 137(16): 2231-2242, 2021 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33512413
3.
Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A.
Haemophilia
; 29(1): 90-99, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36271487
4.
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.
Haemophilia
; 28(6): 1033-1043, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35905294
5.
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
N Engl J Med
; 379(9): 811-822, 2018 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-30157389
6.
Low immunogenicity of emicizumab in persons with haemophilia A.
Haemophilia
; 27(6): 984-992, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34480814
7.
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors.
Haemophilia
; 27(2): 221-228, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33506955
8.
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
Haemophilia
; 27(5): 854-865, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34171159
9.
Effect of varying degrees of renal impairment on the pharmacokinetics and tolerability of taspoglutide.
Diabetes Obes Metab
; 19(4): 537-544, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27981717
10.
Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies.
Res Pract Thromb Haemost
; 8(2): 102364, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38559572
11.
Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks.
Res Pract Thromb Haemost
; 8(1): 102306, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38282901
12.
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies.
Blood Adv
; 6(24): 6140-6150, 2022 12 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35939785
13.
Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder.
J Clin Psychiatry
; 81(4)2020 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32663909
14.
Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials.
Clin Pharmacokinet
; 58(9): 1205-1214, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30968335
15.
Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
Curr Med Res Opin
; 35(12): 2079-2087, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31355677
16.
Reply: RE: Reyes A, Révil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087.
Curr Med Res Opin
; 36(7): 1129-1130, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32180474
Resultados
1 -
16
de 16
1
Próxima >
>>